Immunotherapy plus low-dose bevacizumab for recurrent astrocytoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (a drug that blocks blood vessel growth to tumors)—for people with astrocytoma that has come back. The goal is to see if this combination can slow or stop the tumor's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with astrocytoma (a type of brain tumor).
- You had your surgery at Henan Provincial People's Hospital, and a small reservoir was placed under the scalp during surgery to collect fluid from the tumor site.
- It has been more than 28 days since your surgery and you have recovered well.
- You are able to care for yourself and perform most daily activities (Karnofsky score of 70 or higher).
- You have not had more than two recurrences of your tumor.
- If you have had prior treatments like bevacizumab or certain immunotherapies (PD-1/PD-L1/CTLA-4), you may not be eligible.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs for people with glioblastoma that has come back after treatment with bevacizumab (a drug that targets blood vessel growth). The goal is to see if this new combination can shrink the tumor or slow its growth.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
This Phase 2 trial tests an immune treatment (sintilimab, an anti–PD-1 antibody) together with low-dose bevacizumab (Avastin) to treat oligodendroglioma that has come back, including cases detected by tumor DNA in body fluid. It aims to slow or control tumor growth and help reduce symptoms by targeting both the tumor and its blood supply.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This trial tests a combination of two medications—irinotecan liposomes (a chemotherapy drug wrapped in fat particles) and bevacizumab (a drug that cuts off blood supply to tumors)—for people whose glioma (a type of brain tumor) has come back or worsened after initial treatment. The goal is to see if this combination can help control the tumor.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
Hear when a new Astrocytoma of Brain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.